These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19635404)

  • 21. Utility of C-reactive protein for cardiovascular risk stratification across three age groups in subjects without existing cardiovascular diseases.
    Hamer M; Chida Y; Stamatakis E
    Am J Cardiol; 2009 Aug; 104(4):538-42. PubMed ID: 19660608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CVD risk assessment: do we need the metabolic syndrome or better global cardiometabolic risk calculators?
    Després JP
    Int J Obes (Lond); 2008 May; 32 Suppl 2():S1-4. PubMed ID: 18469833
    [No Abstract]   [Full Text] [Related]  

  • 23. Review of tools of cardiovascular disease risk stratification: interpretation, customisation and application in clinical practice.
    Chia YC
    Singapore Med J; 2011 Feb; 52(2):116-23. PubMed ID: 21373738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Documentation of cardiovascular risk factors.
    McBain L
    N Z Med J; 2008 Mar; 121(1270):106. PubMed ID: 18364763
    [No Abstract]   [Full Text] [Related]  

  • 25. Validity of self-reported cardiovascular disease events in comparison to medical record adjudication and a statewide hospital morbidity database: the AusDiab study.
    Barr EL; Tonkin AM; Welborn TA; Shaw JE
    Intern Med J; 2009 Jan; 39(1):49-53. PubMed ID: 19290982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining a rational approach to screening for cardiovascular risk in asymptomatic patients.
    Greenland P; Lloyd-Jones D
    J Am Coll Cardiol; 2008 Jul; 52(5):330-2. PubMed ID: 18652939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale, design and population description of the CREDENCE study: cardiovascular risk equations for diabetes patients from New Zealand and Chinese electronic health records.
    Liang J; Pylypchuk R; Tang X; Shen P; Liu X; Chen Y; Tan J; Wu J; Zhang J; Lu P; Lin H; Gao P; Jackson R
    Eur J Epidemiol; 2021 Oct; 36(10):1085-1095. PubMed ID: 34420154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk in cardiovascular disease. Joint British societies recommend their computer program for risk calculations.
    Durrington PN
    BMJ; 2000 Jul; 321(7254):174-5. PubMed ID: 10950540
    [No Abstract]   [Full Text] [Related]  

  • 29. Future directions in cardiovascular disease risk prediction.
    Doust JA; Bonner C; Bell KJL
    Aust J Gen Pract; 2020 Aug; 49(8):488-494. PubMed ID: 32738856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zeroing in on depression as a cardiovascular risk factor. Can lifting mood improve outcomes?
    Ford DE
    Postgrad Med; 2003 Dec; 114(6 Suppl Managing Depression):6-13. PubMed ID: 19667660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preventing cardiovascular disease: a review of the effectiveness of identifying the people with familial hypercholesterolaemia in New Zealand.
    Muir LA; George PM; Laurie AD; Reid N; Whitehead L
    N Z Med J; 2010 Nov; 123(1326):97-102. PubMed ID: 21326404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular disease risk profile tools and new zealand--the best way forward?
    Boland P; Moriarty H
    J Prim Health Care; 2009 Dec; 1(4):328-31. PubMed ID: 20690346
    [No Abstract]   [Full Text] [Related]  

  • 33. Biomarkers for prediction of cardiovascular events.
    Mints G; Shah NR
    N Engl J Med; 2007 Apr; 356(14):1473-4; author reply 1474-5. PubMed ID: 17415904
    [No Abstract]   [Full Text] [Related]  

  • 34. Vitamin D and the cardiovascular system.
    Artaza JN; Mehrotra R; Norris KC
    Clin J Am Soc Nephrol; 2009 Sep; 4(9):1515-22. PubMed ID: 19696220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk assessment and management of cardiovascular disease in New Zealand.
    Williams M
    N Z Med J; 2003 Nov; 116(1185):U661. PubMed ID: 14615803
    [No Abstract]   [Full Text] [Related]  

  • 36. [Primary prevention of cardiovascular disease].
    Katić T; Sakić I; Bergovec M
    Acta Med Croatica; 2009 Feb; 63(1):71-4. PubMed ID: 19681467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arterial stiffness, vascular disease, and risk of cardiovascular events.
    Cohn JN
    Circulation; 2006 Feb; 113(5):601-3. PubMed ID: 16461830
    [No Abstract]   [Full Text] [Related]  

  • 38. Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy.
    Khakpour H; Frishman WH
    Cardiol Rev; 2009; 17(5):222-9. PubMed ID: 19690473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hormones and cardiovascular disease: a shift in paradigm with clinical consequences?
    van Zaane B; Reuwer AQ; Büller HR; Kastelein JJ; Gerdes VE; Twickler MT
    Semin Thromb Hemost; 2009 Jul; 35(5):478-87. PubMed ID: 19739038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of current knowledge on CVD prevention.
    Roy A; Prabhakaran D
    Indian Heart J; 2008; 60(2 Suppl B):B23-8. PubMed ID: 19359760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.